These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 3566246)

  • 21. Eucaryotic cells protect Borrelia burgdorferi from the action of penicillin and ceftriaxone but not from the action of doxycycline and erythromycin.
    Brouqui P; Badiaga S; Raoult D
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1552-4. PubMed ID: 8726038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro susceptibilities of Leptospira spp. and Borrelia burgdorferi isolates to amoxicillin, tilmicosin, and enrofloxacin.
    Kim D; Kordick D; Divers T; Chang YF
    J Vet Sci; 2006 Dec; 7(4):355-9. PubMed ID: 17106227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erythromycin resistance in Borrelia burgdorferi.
    Terekhova D; Sartakova ML; Wormser GP; Schwartz I; Cabello FC
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3637-40. PubMed ID: 12384380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.
    Hunfeld KP; Wichelhaus TA; Rödel R; Acker G; Brade V; Kraiczy P
    Antimicrob Agents Chemother; 2004 Jan; 48(1):344-7. PubMed ID: 14693564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro susceptibility of Borrelia burgdorferi and Borrelia hermsii to ten antimicrobial agents.
    Sambri V; Massaria F; Cevenini R; La Placa M
    J Chemother; 1990 Dec; 2(6):348-50. PubMed ID: 2093104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro antibiotic susceptibilities of Borrelia isolates from erythema migrans lesion of Lyme disease patients in Japan.
    Masuzawa T; Yamada K; Kawabata H; Yanagihara Y
    Microbiol Immunol; 1994; 38(5):399-402. PubMed ID: 7935067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.
    Agger WA; Callister SM; Jobe DA
    Antimicrob Agents Chemother; 1992 Aug; 36(8):1788-90. PubMed ID: 1416868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro culture system to determine MICs and MBCs of antimicrobial agents against Treponema pallidum subsp. pallidum (Nichols strain).
    Norris SJ; Edmondson DG
    Antimicrob Agents Chemother; 1988 Jan; 32(1):68-74. PubMed ID: 2964810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of patients with persistent symptoms and a history of Lyme disease.
    Donta ST
    N Engl J Med; 2001 Nov; 345(19):1424; author reply 1425. PubMed ID: 11794180
    [No Abstract]   [Full Text] [Related]  

  • 30. In vitro activity of vancomycin against the spirochete Borrelia burgdorferi.
    Dever LL; Jorgensen JH; Barbour AG
    Antimicrob Agents Chemother; 1993 May; 37(5):1115-21. PubMed ID: 8517700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto.
    Sicklinger M; Wienecke R; Neubert U
    J Clin Microbiol; 2003 Apr; 41(4):1791-3. PubMed ID: 12682190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro susceptibility of Borrelia burgdorferi isolates to three antibiotics commonly used for treating equine Lyme disease.
    Caol S; Divers T; Crisman M; Chang YF
    BMC Vet Res; 2017 Sep; 13(1):293. PubMed ID: 28962614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kill kinetics of Borrelia burgdorferi and bacterial findings in relation to the treatment of Lyme borreliosis.
    Preac Mursic V; Marget W; Busch U; Pleterski Rigler D; Hagl S
    Infection; 1996; 24(1):9-16. PubMed ID: 8852456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.
    Pavia C; Inchiosa MA; Wormser GP
    Antimicrob Agents Chemother; 2002 Jan; 46(1):132-4. PubMed ID: 11751123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antibiotic resistance and serotypes of Streptococcus pneumoniae in Zurich (1984-1985)].
    Wüst J; Kayser FH; Morenzoni G
    Schweiz Med Wochenschr; 1987 Jun; 117(23):868-73. PubMed ID: 3649919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Failure of topical antibiotics to prevent disseminated Borrelia burgdorferi infection following a tick bite in C3H/HeJ mice.
    Wormser GP; Daniels TJ; Bittker S; Cooper D; Wang G; Pavia CS
    J Infect Dis; 2012 Mar; 205(6):991-4. PubMed ID: 21930606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infection of Syrian hamsters with Lyme disease spirochetes.
    Johnson RC; Marek N; Kodner C
    J Clin Microbiol; 1984 Dec; 20(6):1099-101. PubMed ID: 6520220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro susceptibility of isolates of Borrelia burgdorferi s.l. to antimicrobial agents.
    Santino I; Scazzocchio F; Ciceroni L; Ciarrocchi S; Sessa R; Del Piano M
    Int J Immunopathol Pharmacol; 2006; 19(3):545-9. PubMed ID: 17026839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.
    Levin JM; Nelson JA; Segreti J; Harrison B; Benson CA; Strle F
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1444-6. PubMed ID: 8363373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of sixty-five non-oral clinical isolates of the Streptococcus milleri group to seven antimicrobial agents.
    Horton WA; Drucker DB; Jacob AE; Hillier VF
    Microbios; 1992; 71(287):125-34. PubMed ID: 1453983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.